{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:55:45Z","timestamp":1769097345532,"version":"3.49.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French National Agency for AIDS and Viral Hepatitis Research"},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011099","name":"Deutsche Gesellschaft f\u00fcr Internationale Zusammenarbeit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011099","name":"GIZ","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Initiative for Impact Evaluation, Inc"},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/jac\/dky428","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T19:18:06Z","timestamp":1539976686000},"page":"473-479","source":"Crossref","is-referenced-by-count":18,"title":["Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART"],"prefix":"10.1093","volume":"74","author":[{"given":"Anne","family":"Derache","sequence":"first","affiliation":[{"name":"Africa Health Research Institute (AHRI), KwaZulu-Natal, South Africa"},{"name":"Division of Infection and Immunity, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collins C","family":"Iwuji","sequence":"additional","affiliation":[{"name":"Africa Health Research Institute (AHRI), KwaZulu-Natal, South Africa"},{"name":"Institute for Global Health, University College London, London, UK"},{"name":"Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siva","family":"Danaviah","sequence":"additional","affiliation":[{"name":"Africa Health Research Institute (AHRI), KwaZulu-Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Giandhari","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, F-75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulio","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Dabis","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux, ISPED, Centre INSERM 1219, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[{"name":"Africa Health Research Institute (AHRI), KwaZulu-Natal, South Africa"},{"name":"Division of Infection and Immunity, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Africa Health Research Institute (AHRI), KwaZulu-Natal, South Africa"},{"name":"Division of Infection and Immunity, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"key\n\t\t\t\t2019012509445611800_dky428-B1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B2","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/QAD.0000000000000906","article-title":"Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo","volume":"29","author":"Konou","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B4","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","article-title":"Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey","volume":"3","author":"\u00c1vila-R\u00edos","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study","volume":"12","author":"Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(16)30469-8","article-title":"Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study","volume":"17","author":"Gregson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B7","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B8","author":"USAID","year":"2017"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7196\/SAMJ.2017.v107i1.12058","article-title":"Cutting the cost of South African antiretroviral therapy using newer, safer drugs","volume":"107","author":"Venter","year":"2016","journal-title":"S Afr Med J"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B11","volume-title":"Surveillance Drug Resistance Mutation (SDRM) Worksheet: NRTIs","author":"Rhee","year":"2016"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B12","author":"ViiV Healthcare"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B13","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B14","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(17)30205-9","article-title":"Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial","volume":"5","author":"Iwuji","year":"2018","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B15","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1128\/JCM.01516-12","article-title":"Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes","volume":"50","author":"Gall","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B16","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/bioinformatics\/bts199","article-title":"Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data","volume":"28","author":"Kearse","year":"2012","journal-title":"Bioinformatics"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B17","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B18","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1128\/AAC.01490-15","article-title":"HIV drug resistance testing by high-multiplex \u201cwide\u201d sequencing on the MiSeq instrument","volume":"59","author":"Lapointe","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B19","volume-title":"Algorithm for the Use of Genotypic HIV-1 Resistance Data (Version Rega v10.0.0","author":"Camacho","year":"2017"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B21","author":"WHO","year":"2016"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkw376","article-title":"Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute\/recent HIV infection","volume":"72","author":"Ambrosioni","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B23","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"Primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadell\u00e0","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B24","volume-title":"Abstracts of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2018","author":"Nguyen"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B25","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/jac\/dkx195","article-title":"Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice","volume":"72","author":"Heredia","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B26","doi-asserted-by":"crossref","first-page":"e547\u201354.","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B27","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains HIV-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/aid.2017.0184","article-title":"Dolutegravir-based regimens are active in integrase strand transfer inhibitor-naive patients with nucleoside reverse transcriptase inhibitor resistance","volume":"34","author":"Demarest","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of dolutegravir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations","volume":"51","author":"S\u00f6rstedt","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/jac\/dkw583","article-title":"Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa","volume":"72","author":"Goodall","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B32","doi-asserted-by":"crossref","first-page":"e20208.","DOI":"10.1371\/journal.pone.0020208","article-title":"A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1","volume":"6","author":"Coutsinos","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B33","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B34","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/135965350400900102","article-title":"Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors","volume":"9","author":"Lanier","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/01.aids.0000131355.44834.e4","article-title":"Phenotypic impact of HIV reverse transcriptase M184I\/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance","volume":"18","author":"Ross","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1128\/AAC.41.5.1094","article-title":"Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89","volume":"41","author":"Tisdale","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/095632020701800603","article-title":"The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R+M184V","volume":"18","author":"Ly","year":"2007","journal-title":"Antivir Chem Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B40","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B41","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3218","article-title":"Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study","author":"Peters","year":"2018","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.18433\/J39S3T","article-title":"Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis","volume":"18","author":"Tangamornsuksan","year":"2015","journal-title":"J Pharm Pharm Sci"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B43","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/S2352-3018(15)00225-8","article-title":"Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis","volume":"3","author":"Jesson","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B44","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/cid\/civ437","article-title":"Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy","volume":"61","author":"Siberry","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"Group","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012509445611800_dky428-B46","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/2\/473\/27524691\/dky428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T09:12:44Z","timestamp":1662282764000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/2\/473\/5150591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,10,31]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky428","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,10,31]]}}}